ABS ePoster Library

Background: Adenoid Cystic carcinoma of the breast is rare and thought to carry a good prognosis. There is currently no treatment consensus. Aim: To assess management and outcomes for adenoid cystic carcinoma of the breast in our network. Methods: We retrospectively collected data on all patients with adenoid cystic breast cancer in the Yorkshire Cancer Network between 2000-2013. Cases were identified from hospital pathology databases. Both pathology and clinical databases were used. Data included patient demographics, clinical presentation, imaging findings, pathological parameters, treatment details and outcomes. Data was analysed using Excel and SPSS. Results: There were 11 new cases of adenoid cystic breast cancer across the Yorkshire Cancer Network. The average age at diagnosis was 56 years (range: 31-82). Pathological grade: 6 grade 1, 5 grade 2. 1 was weakly ER and PR positive, the rest were triple negative; all were node negative. All patients underwent surgical management: 8 Wide Local Excisions (WLE), 2 with Sentinel Lymph Node Biopsy (SLNB) and 2 with Axillary Lymph Node Sampling. 1 required completion mastectomy and 3 underwent mastectomy and SLNB. All patients received adjuvant Radiotherapy 40Gy/15 fractions and 1 had an additional boost of 10Gy/5 fractions. No patients received chemotherapy. Local control rate was 100%. 2 patients died from metastatic neuroendocrine carcinoma, and one from metastatic adenoid cystic carcinoma of solid variant. Conclusions: Our study shows that hypo-fractionated radiotherapy achieves excellent local control. It is of interest that 2 patients developed metastatic neuroendocrine cancer suggesting a possible link between these pathologies.